News Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-11-06 EST			5-day change	1st Jan Change
166.89 ^USD	-0.41%		-2.22%	+35.97%

11-06	Gilead Sciences Says Twice-Yearly Lenacapavir Shows Higher PrEP Persistence in Phase 2 Trial	MT
11-05	Maxim Adjusts Price Target on Gilead Sciences to $200 From $165	MT

All News

Mentions Relevance

11-06	Gilead Sciences Says Twice-Yearly Lenacapavir Shows Higher PrEP Persistence in Phase 2 Trial	MT
11-06	New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention	BU
11-05	Maxim Adjusts Price Target on Gilead Sciences to $200 From $165	MT
11-05	Gilead Sciences' Phase 3 Livdelzi Study Shows Improvements in Adults With Primary Biliary Cholangitis	MT
11-05	Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)	BU
11-05	Gilead Sciences, Inc. Reports Detailed Results From Phase 3 IDEAL Study Demonstrating Livdelzi Achieves ALP Normalization Composite Endpoint in Adults With Primary Biliary Cholangitis	CI
11-04	Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026	BU
11-04	DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167	MT
11-02	Dr Reddy's gets tentative US FDA nod for generic HIV prevention	RE
11-02	Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow	BU
11-02	Gilead Sciences Announces Presentation of Late-Breaking Clinical Data and Real-World Evidence At Hiv Glasgow	CI
10-30	Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences	BU
10-30	Gilead's HIV Franchise Supports Growth Outlook, RBC Says	MT
10-30	UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy Rating	MT
10-30	Needham Adjusts Price Target on Gilead Sciences to $200 From $170	MT
10-30	Leerink Partners Adjusts Price Target on Gilead Sciences to $145 From $129	MT
10-30	RBC Raises Price Target on Gilead Sciences to $131 From $126, Keeps Sector Perform Rating	MT
10-29	Gilead Sciences, Inc., Q3 2026 Earnings Call, Oct 29, 2026
10-29	Gilead Sciences : Third Quarter 2026 Summary of Remarks	PU
10-29	Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028	RE
10-29	Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028	RE
10-29	Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength	DJ
10-29	Gilead Q3 Adjusted Earnings, Revenue Rise; Updates Guidance	MT
10-29	(GILD) Gilead Sciences Expects Full Year 2026 Adjusted Loss Range of $1.20 - $0.85, vs. FactSet Est of -$0.40 Loss	MT
10-29	Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q3 Revenue $8.30B, vs. FactSet Est of $7.81B	MT